Explore the words cloud of the CytoPro project. It provides you a very rough idea of what is the project "CytoPro" about.
The following table provides information about the project.
|Coordinator Country||Denmark [DK]|
|Total cost||2˙445˙232 €|
|EC max contribution||1˙711˙662 € (70%)|
1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
|Duration (year-month-day)||from 2018-11-01 to 2021-10-31|
Take a look of project's partnership.
|1||CYTOTRACK APS||DK (LYNGBY)||coordinator||1˙692˙762.00|
|2||HVD BIOTECH VERTRIEBSGESELLSCHAFT MBH||AT (WIEN)||participant||18˙900.00|
In Europe, approximately 1 in 2 people will get cancer in their lifetimes. State-of-the-art cancer treatments can be tailored to the genetic make-up of a patient’s tumour, making them highly effective at fighting cancer. However, these very expensive treatments, which cost the society €1.5bn each year, can become ineffective over time due to genetic mutations in the tumours. Currently, there is no diagnostic tool available to regularly monitor for such mutations.
CytoTrack has developed the CT11™, a unique blood test that helps oncologists to detect and monitor tumour mutations, enabling them to select the right treatment at the right time. The CT11™ can rapidly identify and isolate Circulating Tumour Cells (CTCs) in the bloodstream to provide up-to-date genetic information without invasive biopsies. Whilst our technology has been proven in the research environment, this CytoPro project will refine, demonstrate and clinically validate the CT11™ for use in metastatic Colorectal Cancer (mCRC) and prepare the device for clinical market introduction.
A successful project will make the CT11™ the first next-generation cancer blood test on the clinical market. It will allow oncologists to optimise therapies more quickly in response to tumour mutations, extending survival rates up to half a year, avoiding unnecessary side-effects and increasing cost effectiveness of the treatment by 10-20%, which could save €15,000 per treatment.
The market for CTC technology is expected to reach €7.8 billion by 2020 and, as the first clinically approved device of its type, we expect the CT11™ to generate rapid business growth for CytoTrack, resulting in an annual revenue of €41m and a profit of €13m by 2026.
The team assembled for CytoPro has an enviable track record in commercialising medical innovations and possesses all the skills and resources to successfully deliver the clinical trials and effectively exploit the results for the benefit of our business and for Europe.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CYTOPRO" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "CYTOPRO" are provided by the European Opendata Portal: CORDIS opendata.
Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any contRead More
Smart Nursing BraRead More
IOT and cloud computing for online medical analysis service platformRead More